Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial
October 03, 2017 01:00 ET
|
Celyad SA
First ever morphologic complete response (MLFS1) with gene-engineered T cells without prior pre-conditioning chemotherapy for a patient with relapsed refractory acute myeloid leukemia (AML). ...
Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference
September 20, 2017 16:30 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell...
Celyad Reports First Half 2017 Financial Results and Operational Progress
August 29, 2017 01:00 ET
|
Celyad SA
Celyad’s management will host a conference call at 2pm CEST / 8am EDT today Strong progress in THINK trial with first signals of clinical activity in solid tumorsNon-exclusive license agreement...
Celyad announces new agreements with Celdara Medical and Dartmouth College
August 04, 2017 01:00 ET
|
Celyad SA
Ongoing clinical trial development boosts Celyad’s confidence in the future of its oncology assetsCelyad to receive an increased share of future revenues in exchange for $25M worth of cash and Celyad...
Celyad announces initiation of the SHRINK trial
July 20, 2017 01:00 ET
|
Celyad SA
SHRINK study to evaluate the synergetic effect of the concurrent administration of CYAD-01 (CAR-T NKG2D) with standard chemotherapy in patients suffering from metastatic colorectal cancer ...
Celyad publishes additional pre-clinical data in support of THINK trial
June 21, 2017 05:00 ET
|
Celyad SA
Review of NKR-2 pre-clinical work published in Future Oncology In vitro efficacy on various cancer models In vivo evidence of efficacy in a human pancreatic model MONT-SAINT-GUIBERT, Belgium, June ...
Celyad reports promising early results at first dose level of the solid arm of the THINK trial
June 19, 2017 01:00 ET
|
Celyad SA
Two metastatic colorectal cancer patients reported as Stable Disease at 3-month follow-upNo toxicity signals reported up to now MONT-SAINT-GUIBERT, Belgium, June 19, 2017 (GLOBE NEWSWIRE) -- ...
Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
May 30, 2017 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 30, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...
Celyad Announces First Quarter 2017 Business Update
May 19, 2017 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, May 19, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of cell therapies, today provided...
FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®
May 11, 2017 01:00 ET
|
Celyad SA
Celyad intends to leverage this designation to accelerate the search for a strategic partnerDesignation granted on the strength of the evidence in the subset of patients that were responders at 9...